Skip to main content

Published locations for IBD: More patients on vedolizumab vs. anti-TNFs at 2 years

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. IBD: More patients on vedolizumab vs. anti-TNFs at 2 years

User login

  • Reset your password
  • /content/ibd-more-patients-vedolizumab-vs-anti-tnfs-2-years
  • /clinicianreviews/article/261578/gastroenterology/ibd-more-patients-vedolizumab-vs-anti-tnfs-2-years
  • /familypracticenews/article/261578/gastroenterology/ibd-more-patients-vedolizumab-vs-anti-tnfs-2
  • /gihepnews/article/261578/gastroenterology/ibd-more-patients-vedolizumab-vs-anti-tnfs-2-years
  • /internalmedicinenews/article/261578/gastroenterology/ibd-more-patients-vedolizumab-vs-anti-tnfs-2
  • /internalmedicine/article/261578/gastroenterology/ibd-more-patients-vedolizumab-vs-anti-tnfs-2-years
  • /familymedicine/article/261578/gastroenterology/ibd-more-patients-vedolizumab-vs-anti-tnfs-2-years